D. Boral Capital Reaffirms “Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital’s target price suggests a potential upside of 444.66% from the company’s previous close.

A number of other research firms also recently weighed in on HUMA. Piper Sandler set a $6.00 target price on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Benchmark upped their target price on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. TD Cowen restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Price Performance

Shares of HUMA stock opened at $4.59 on Tuesday. Humacyte has a 12-month low of $2.80 and a 12-month high of $9.97. The firm has a market capitalization of $577.70 million, a price-to-earnings ratio of -3.43 and a beta of 1.32. The business has a 50 day simple moving average of $4.54 and a 200 day simple moving average of $5.65.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same period last year, the company earned ($0.25) earnings per share. On average, equities analysts anticipate that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Activity

In other news, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. This represents a 13.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,500,000 shares of company stock worth $6,606,799. Insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Hedge funds have recently modified their holdings of the business. Brookstone Capital Management purchased a new stake in shares of Humacyte in the fourth quarter valued at $56,000. ACT Wealth Management LLC acquired a new position in shares of Humacyte in the fourth quarter worth $57,000. Concurrent Investment Advisors LLC acquired a new position in shares of Humacyte in the third quarter worth $75,000. FORA Capital LLC acquired a new position in shares of Humacyte in the third quarter worth $96,000. Finally, Profund Advisors LLC acquired a new position in shares of Humacyte in the second quarter worth $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.